Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays

被引:11
作者
Ananthanarayanan, Viju [1 ]
Deaton, Ryan J. [1 ]
Amatya, Anup [2 ]
Macias, Virgilia [1 ]
Luther, Ed [3 ]
Kajdacsy-Balla, Andre [1 ]
Gann, Peter H. [1 ]
机构
[1] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA
[2] Univ Illinois, Div Epidemiol & Biostat, Chicago, IL 60612 USA
[3] CompuCyte Corp, Cambridge, MA USA
关键词
Prostate cancer; Prognosis; p27(Kip1); Automated image analysis; Tissue microarray; KINASE INHIBITOR P27; PROTEIN EXPRESSION; P27(KIP1) PROTEIN; FREE SURVIVAL; CYCLIN; ADENOCARCINOMA; DISEASE; PROLIFERATION; ASSOCIATION; CARCINOMA;
D O I
10.1016/j.humpath.2010.10.006
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Previous investigations have linked decreased nuclear expression of the cell cycle inhibitor p27 with poor outcome in prostate cancer. However, these reports are inconsistent regarding the magnitude of that association and its independence from other predictors. Moreover, cytoplasmic translocation of p27 has been proposed as a negative prognostic sign. Given the cost and accuracy limitations of manual. scoring, particularly of tissue microarrays, we determined if laser-based fluorescence microscopy could provide automated analysis of p27 in both nuclear and cytoplasmic locations and, thus, clarify its significance as a prognostic biomarker. We constructed tissue microarrays covering 202 recurrent cases (rising prostate-specific antigen) and 202 matched controls without recurrence. Quadruplicate tumor samples encompassed 5 slides and 1616 cancer histospots. Cases and controls matched on age, Gleason grade, stage, and hospital. We immunolabeled epithelial cytoplasm with Alexafluor 647, p27 with Alexafluor 488, and nuclei with 4c6-diamidino-2-phenylindole center dot 2HCl. Slides were scanned on an iCys laser scanning cytometer (CompuCyte Corp, Cambridge, MA). Nuclear crowding required a stereological approach random arrays of circles (phantoms) were layered on images and the content of each phantom was analyzed in scatter plots. Both nuclear and cytoplasmic p27 were significantly lower in cases versus controls (P=.014 and P=.004, respectively). Regression models controlling for matching variables plus prostate-specific antigen showed strong linear trends for increased risk of recurrence with lower p27 in both nucleus and cytoplasm (highest versus lowest quartile; odds ratio, 0.35; P=.006). Manual scoring identified an inverse association between p27 expression and tumor grade but no independent association with recurrence. In conclusion, we developed an automated method for subcellular scoring of p27 without the need to segment individual cells. Our method identified a strong relationship, independent of tumor grade, stage, and prostate-specific antigen, between p27 expression regardless of subcellular location and prostate cancer recurrence. This relationship was not observed with manual scoring. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:873 / 881
页数:9
相关论文
共 30 条
[1]   A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers [J].
Camp, Robert L. ;
Neumeister, Veronique ;
Rimm, David L. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) :5630-5637
[2]  
Cheng JD, 1999, CLIN CANCER RES, V5, P1057
[3]   Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma [J].
Cote, RJ ;
Shi, Y ;
Groshen, S ;
Feng, AC ;
Cordon-Cardo, C ;
Skinner, D ;
Lieskovosky, G .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (12) :916-920
[4]  
Cregger M, 2006, ARCH PATHOL LAB MED, V130, P1026
[5]  
Drobnjak M, 2003, CLIN CANCER RES, V9, P2613
[6]  
Erdamar S, 1999, MODERN PATHOL, V12, P751
[7]  
Esposito V, 1997, CANCER RES, V57, P3381
[8]   Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression [J].
Freedland, SJ ;
DeGregorio, F ;
Sacoolidge, JC ;
Elshimali, YI ;
Csathy, GS ;
Elashoff, DA ;
Reiter, RE ;
Aronson, WJ .
UROLOGY, 2003, 61 (06) :1187-1192
[9]  
Guo YP, 1997, CLIN CANCER RES, V3, P2269
[10]  
Halvorsen OJ, 2003, CLIN CANCER RES, V9, P1474